News

Prof Jianjun Wang was invited to attend Tigermed's ASCO Pre-Event Webinar as a Speaker to present Qurgen’s breakthrough cell converting cancer therapy and the recent progress of its Phase I clinical trial.

No infusion related reactions (IRRs) were observed in patients enrolled in the ongoing Qurgen Clinical trial using a 48-hour continuous infusion pump. This modified drug infusion regimen significantly enhanced the safety of SON-DP treatment.

Qurgen reported that numbers of patients with advanced solid tumors had received low-dose SON-DP treatment (2-4.5 mg/kg) for over 18 months. Sustained tumor reduction was observed throughout the 18-month treatment period in some of these patients. In addition, no teratoma formation has been detected in any of the patients. These founding support a favorable safety profile of SON-DP based cellular converting therapy.

 Qurgen has expanded the clinical trial of its cell-converting cancer therapy in the following four clinical sites.

Fuent (Qurgen’s China subsidiary) has expanded its cell-converting cancer therapy in the following five clinical sites.

In December 2025, Qurgen Inc. was named one of the World's Top 10 Innovative Companies by MedHealth magazine.

Fuent (Qurgen’s China subsidiary) has initiated its Phase I clinical trial in China following IND approval from Center for Drug Evaluation (CDE) The study is being conducted at the following clinical sites.

Fuent (Qurgen’s China subsidiary) officially initiated operations at its GMP manufacturing facility located in Suzhou High-tech Zone, China. As of June 2025, the facility has successfully completed four manufacturing batches of SON-DP, all quality attributes meet the regulatory standards set by both FDA and NMPA for protein drug products. These GMP-manufactured drug products will be used in both Qurgen’s and Fuent’s ongoing clinical trials.